Haleon plc (HLN)vsIncannex Healthcare Ltd ADR (IXHL)
HLN
Haleon plc
$9.19
-0.33%
HEALTHCARE · Cap: $44.28B
IXHL
Incannex Healthcare Ltd ADR
$3.26
+0.31%
HEALTHCARE · Cap: $39.12M
Smart Verdict
WallStSmart Research — data-driven comparison
HLN leads profitability with a 14.5% profit margin vs 0.0%. HLN earns a higher WallStSmart Score of 51/100 (C-).
HLN
Buy51
out of 100
Grade: C-
IXHL
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Strong operational efficiency at 23.9%
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
2.2% revenue growth
Grey zone — moderate risk
Earnings declined 4.5%
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : HLN
The strongest argument for HLN centers on Price/Book, Operating Margin.
Bull Case : IXHL
The strongest argument for IXHL centers on Price/Book, Debt/Equity.
Bear Case : HLN
The primary concerns for HLN are PEG Ratio, Revenue Growth, Altman Z-Score.
Bear Case : IXHL
The primary concerns for IXHL are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
IXHL carries more volatility with a beta of 2.81 — expect wider price swings.
HLN is growing revenue faster at 2.2% — sustainability is the question.
HLN generates stronger free cash flow (792M), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.
Bottom Line
HLN scores higher overall (51/100 vs 24/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Haleon plc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Haleon plc (HLN) is a leading global consumer health company, emerging as a spin-off from GlaxoSmithKline, dedicated to providing innovative health solutions through a robust portfolio of trusted brands, including Sensodyne, Panadol, and Voltaren. Focused on key segments such as oral care, pain relief, and dietary supplements, Haleon addresses evolving consumer needs while leveraging strong brand equity for sustained market presence. The company's commitment to sustainability and ongoing innovation, alongside strategic investments in product development, positions Haleon favorably for long-term growth and enhanced health outcomes, ultimately maximizing value for shareholders.
Visit Website →Incannex Healthcare Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Incannex Healthcare Limited is engaged in the research, development and sale of medicinal cannabinoid products in Australia. The company is headquartered in Sydney, Australia.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?